Benefits and Risks of early market access
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Presentation
- By: HUCKLE, Richard (Pope Woodhead & Associates Ltd, UK)
Early access pathways are evolving, requiring multiple stakeholder interactions (including regulators, HTA bodies/payers and patients) with the aim to facilitate and accelerate development, marketing authorisation and access of medicines to patients in areas of high unmet needs.
Early access decisions are particularly challenging due to the.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.